Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer

Adagene Inc. (NASDAQ:ADAG) is one of the 10 Unstoppable Stocks That Could Double Your Money.

Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study will combine Adagene’s muzastotug/ADG126, which is a masked anti-CTLA-4 SAFEbody, with Incyte’s INCA33890, a bispecific antibody targeting TGFβR2 and PD-1.

This Phase 1 trial, expected to begin in 2026, will focus on third-line patients both with and without liver metastases, a group that typically faces a poor prognosis and limited response to standard immunotherapies. The collaboration uses muzastotug’s potential as a backbone therapy, designed to increase the therapeutic index by selectively activating in the tumor microenvironment. While Incyte will sponsor and conduct the trial, Adagene will provide the clinical supply of muzastotug.

Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer

Photo by National Cancer Institute on Unsplash

This marks a significant expansion of muzastotug’s clinical portfolio, which already includes promising data in combination with pembrolizumab, where it achieved a 31% overall response rate in specific high-dose cohorts for late-line MSS CRC patients. Additionally, Adagene Inc. (NASDAQ:ADAG) recently released updated data from its ongoing Phase 1b/2 study, showing that muzastotug in combination with pembrolizumab achieved a median overall survival of 19.8 months in the 10 mg/kg cohorts.

Adagene Inc. (NASDAQ:ADAG) is a biotechnology company that specializes in monoclonal antibody drugs for cancers. The company’s diverse pipeline of clinical & preclinical oncology candidates includes its lead anti-CTLA-4 antibody ADG126 and various mAb & bispecific programs.

While we acknowledge the risk and potential of ADAG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ADAG and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.